Tanya Siddiqi, MD

High‑risk del17p CLL patients on single‑agent zanubrutinib show durable progression‑free survival, rivaling outcomes in standard‑risk groups.

High-risk DEL17p CLL patients show durable progression-free survival on single-agent zanubrutinib, matching outcomes seen in standard-risk groups.

Six-year data show continuous zanubrutinib keeps CLL controlled longer than bendamustine-rituximab, including high-risk del17p/TP53 patients.

Tanya Siddiqi, MD, discusses how she sees acalabrutinib fitting into the treatment landscape for patients with chronic lymphocytic leukemia following the results from the phase III ASCEND trial.